SUBSCRIBE
SUBSCRIBE
News   FDA

Novartis AG Sight Drug Gets Broader EU Approval

January 7, 2011 | 
1 min read
ZURICH, Jan 7 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) said on Friday the European Commission has approved broader application of its Lucentis drug to treat visually impaired patients, giving sales of the drug a potential boost.
FDA Approvals Europe
Novartis
MORE ON THIS TOPIC
Illustration of young woman standing in front of exit door
FDA
Interim CDER head Høeg is out days after Makary: report
May 15, 2026
 · 
1 min read
 · 
Gabrielle Masson
Illustration showing a downward graph trend
Regulatory
Future of Aardvark’s Prader-Willi drug in doubt as FDA slaps full hold on program
May 15, 2026
 · 
2 min read
 · 
Tristan Manalac
Lightbulb with tangled lines. Problem solving and brainstorming Idea concept. Vector illustration
Gene therapy
REGENXBIO slumps after serious side effects mar Duchenne gene therapy results
May 14, 2026
 · 
3 min read
 · 
Annalee Armstrong
Businessperson group is walking towards career success or a vacant promotion competition. isometric vector illustration.
FDA
Biotech leaders pitch Pazdur as next FDA chief
May 14, 2026
 · 
2 min read
 · 
Annalee Armstrong